Daniel B Soland - Net Worth and Insider Trading

Daniel B Soland Net Worth

The estimated net worth of Daniel B Soland is at least $343,474 dollars as of 2024-07-17. Daniel B Soland is the Director of ACADIA Pharmaceuticals Inc and owns about 10,000 shares of ACADIA Pharmaceuticals Inc (ACAD) stock worth over $186,200. Daniel B Soland is the Director of KalVista Pharmaceuticals Inc and owns about 10,000 shares of KalVista Pharmaceuticals Inc (KALV) stock worth over $152,500. Daniel B Soland is also the Director of DBV Technologies SA and owns about 5,000 shares of DBV Technologies SA (DBVT) stock worth over $4,129. Besides these, Daniel B Soland also holds Aceragen Inc (ACGN) . Details can be seen in Daniel B Soland's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Daniel B Soland has not made any transactions after 2023-08-01 and currently still holds the listed stock(s).

Transaction Summary of Daniel B Soland

To

Daniel B Soland Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Daniel B Soland owns 4 companies in total, including KalVista Pharmaceuticals Inc (KALV) , ACADIA Pharmaceuticals Inc (ACAD) , and Aceragen Inc (ACGN) among others .

Click here to see the complete history of Daniel B Soland’s form 4 insider trades.

Insider Ownership Summary of Daniel B Soland

Ticker Comapny Transaction Date Type of Owner
KALV KalVista Pharmaceuticals Inc 2020-10-01 director
ACAD ACADIA Pharmaceuticals Inc 2019-06-26 director
ACGN Aceragen Inc 2021-03-05 Chief Operating Officer
LIMIT LIMIT 2023-08-01 director

Daniel B Soland Latest Holdings Summary

Daniel B Soland currently owns a total of 4 stocks. Among these stocks, Daniel B Soland owns 10,000 shares of ACADIA Pharmaceuticals Inc (ACAD) as of March 2, 2018, with a value of $186,200 and a weighting of 54.21%. Daniel B Soland owns 10,000 shares of KalVista Pharmaceuticals Inc (KALV) as of September 27, 2019, with a value of $152,500 and a weighting of 44.4%. Daniel B Soland also owns 5,000 shares of DBV Technologies SA (DBVT) as of August 1, 2023, with a value of $4,129 and a weighting of 1.2%. The other 1 stocks Aceragen Inc (ACGN) have a combined weighting of 0.19% among all his current holdings.

Latest Holdings of Daniel B Soland

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ACAD ACADIA Pharmaceuticals Inc 2018-03-02 10,000 18.62 186,200
KALV KalVista Pharmaceuticals Inc 2019-09-27 10,000 15.25 152,500
DBVT DBV Technologies SA 2023-08-01 5,000 0.83 4,129
ACGN Aceragen Inc 2021-03-05 1,697 0.38 645

Holding Weightings of Daniel B Soland


Daniel B Soland Form 4 Trading Tracker

According to the SEC Form 4 filings, Daniel B Soland has made a total of 0 transactions in ACADIA Pharmaceuticals Inc (ACAD) over the past 5 years. The most-recent trade in ACADIA Pharmaceuticals Inc is the acquisition of 10,000 shares on March 2, 2018, which cost Daniel B Soland around $234,900.

According to the SEC Form 4 filings, Daniel B Soland has made a total of 1 transactions in KalVista Pharmaceuticals Inc (KALV) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in KalVista Pharmaceuticals Inc is the acquisition of 10,000 shares on September 27, 2019, which cost Daniel B Soland around $118,700.

According to the SEC Form 4 filings, Daniel B Soland has made a total of 1 transactions in DBV Technologies SA (DBVT) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in DBV Technologies SA is the acquisition of 3,750 shares on August 1, 2023, which cost Daniel B Soland around $24,300.

More details on Daniel B Soland's insider transactions can be found in the Insider Trading History of Daniel B Soland table.

Insider Trading History of Daniel B Soland

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Daniel B Soland Trading Performance

GuruFocus tracks the stock performance after each of Daniel B Soland's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Daniel B Soland is -22.38%. GuruFocus also compares Daniel B Soland's trading performance to market benchmark return within the same time period. The performance of stocks bought by Daniel B Soland within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Daniel B Soland's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Daniel B Soland

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
2 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -21.37 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -22.07 LIMIT LIMIT LIMIT LIMIT LIMIT

Daniel B Soland Ownership Network

Ownership Network List of Daniel B Soland

No Data

Ownership Network Relation of Daniel B Soland

Insider Network Chart

Daniel B Soland Owned Company Details

What does KalVista Pharmaceuticals Inc do?

Who are the key executives at KalVista Pharmaceuticals Inc?

Daniel B Soland is the director of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include CFO and Secretary Benjamin L Palleiko , Chief Scientific Officer Edward P. Feener , and Chief Medical Officer Paul K. Audhya .

KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary

Over the past 18 months, Daniel B Soland made no insider transaction in KalVista Pharmaceuticals Inc (KALV). Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net purchase of 1,251,017 shares made by Venrock Healthcare Capital Partners Iii, L.p. , a net sale of 118,495 shares made by Edward P. Feener , and a net sale of 165,254 shares made by Thomas Andrew Crockett .

In summary, during the past 3 months, insiders sold 62,297 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 0 shares, with a net sale of 62,297 shares. During the past 18 months, 562,698 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 1,251,017 shares were bought by its insiders, resulting in a net purchase of 688,319 shares.

KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

KalVista Pharmaceuticals Inc Insider Transactions

No Available Data

Daniel B Soland Mailing Address

Above is the net worth, insider trading, and ownership report for Daniel B Soland. You might contact Daniel B Soland via mailing address: 4560 Horton Street,m/s R-422, Emeryville Ca 94608.

Discussions on Daniel B Soland

No discussions yet.